Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial

To identify a molecular signature that could be predictive of the clinical response to rituximab (RTX) and elucidate the transcriptomic changes after RTX therapy in patients with rheumatoid arthritis (RA), with the use of whole‐blood transcriptomic profiling.

[1]  M. Dougados,et al.  CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[2]  M. Dougados,et al.  Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial , 2013, Annals of the rheumatic diseases.

[3]  Simon A. Jones,et al.  The problem of choice: current biologic agents and future prospects in RA , 2013, Nature Reviews Rheumatology.

[4]  Saskia Vosslamber,et al.  The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients , 2012, Arthritis Research & Therapy.

[5]  M. Dougados,et al.  Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. , 2011, Arthritis and rheumatism.

[6]  M. Paye,et al.  Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis , 2011, PloS one.

[7]  Diane U. Leong,et al.  A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis , 2011, Science Translational Medicine.

[8]  C. Verweij,et al.  New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. , 2011, Discovery medicine.

[9]  Wei Xu,et al.  Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activator. , 2011, Biochemical and biophysical research communications.

[10]  C. Gabay,et al.  Interleukin-33 biology with potential insights into human diseases , 2011, Nature Reviews Rheumatology.

[11]  M. Dougados,et al.  B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. , 2011, Arthritis and rheumatism.

[12]  Koen Vos,et al.  Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. , 2010, Arthritis and rheumatism.

[13]  P. Emery,et al.  Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. , 2010, Arthritis and rheumatism.

[14]  A. Julià,et al.  Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. , 2009, Pharmacogenomics.

[15]  T. van der Poll,et al.  Analysis of CD97 Expression and Manipulation: Antibody Treatment but Not Gene Targeting Curtails Granulocyte Migration1 , 2008, The Journal of Immunology.

[16]  X. Mariette,et al.  Rituximab: a new therapeutic alternative in rheumatoid arthritis. , 2008, Joint, bone, spine : revue du rhumatisme.

[17]  M. Dougados,et al.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.

[18]  E. G. de la Concha,et al.  Association of the IFIH1-GCA-KCNH7 chromosomal region with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[19]  R. Queiro-Silva,et al.  MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. , 2007, Rheumatology.

[20]  M. Dougados,et al.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[21]  S. Jimenez,et al.  NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis , 2006 .

[22]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[23]  G. Panayi.  B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? , 2005, Rheumatology.

[24]  M. Goldsmith,et al.  Loss of Tolerance and Autoimmunity Affecting Multiple Organs in STAT5A/5B-Deficient Mice 1 , 2003, The Journal of Immunology.

[25]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Haines,et al.  Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. , 2001, Arthritis and rheumatism.

[27]  J. Edwards,et al.  Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. , 2001, Rheumatology.

[28]  I. Wicks,et al.  Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. , 1999, The American journal of pathology.

[29]  D. Chaplin,et al.  B Lymphocytes Induce the Formation of Follicular Dendritic Cell Clusters in a Lymphotoxin α–dependent Fashion , 1998, The Journal of experimental medicine.

[30]  H. Will,et al.  Autoantibodies to the Nuclear Sp100 Protein in Primary Biliary Cirrhosis and Associated Diseases: Epitope Specificity and Immunoglobulin Class Distribution , 1992, Scandinavian journal of immunology.

[31]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[32]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[33]  M. Wood,et al.  Analysis and interpretation of data. , 1978, The Journal of family practice.

[34]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.